Get informed when a big investor buys or sells
+ Follow-2.55
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
International Stem Cell (ISCO) currently reports a P/E ratio of -2.55. That is below the Healthcare sector average of 21.65. Use the charts on this page to explore International Stem Cell's P/E ratio history and peer comparisons.
International Stem Cell's P/E ratio of -2.55 is lower than the Healthcare sector average of 21.65. That is roughly 111.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates International Stem Cell's market price to a fundamental measure such as earnings, sales, or book value. At -2.55, ISCO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -2.55, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.65. From there, open related valuation or income-statement pages for International Stem Cell, and consider following ISCO for alerts when major investors trade the stock.
International Stem Cell is classified in the Healthcare sector. On P/E ratio, it currently shows -2.55 versus a sector average near 21.65. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ISCO with unrelated industries.